Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases

Background: Cancer immunotherapy is rapidly expanding but its clinical efficacy is hampered by immune related adverse events (ir-AE). There is a concern regarding patients with pre-existing auto-immune diseases (PAD) undergoing immunotherapy. Methods: An electronic search was performed (Medline) to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kalliopi Klavdianou, Konstantinos Melissaropoulos, Alexandra Filippopoulou, Dimitrios Daoussis
Formato:	article
Lenguaje:	EN
Publicado:	PCO Convin S.A. 2021
Materias:	immune checkpoint inhibitors cancer immunotherapy pre-existing rheumatic diseases rheumatic diseases Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/5901a31e50854285a3a7d0f1078a6873
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5901a31e50854285a3a7d0f1078a6873
record_format	dspace
spelling	oai:doaj.org-article:5901a31e50854285a3a7d0f1078a68732021-11-08T08:28:47ZShould we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases2529-198X10.31138/mjr.32.3.218https://doaj.org/article/5901a31e50854285a3a7d0f1078a68732021-01-01T00:00:00Zhttp://www.mjrheum.org/assets/files/792/file329_1352.pdfhttps://doaj.org/toc/2529-198XBackground: Cancer immunotherapy is rapidly expanding but its clinical efficacy is hampered by immune related adverse events (ir-AE). There is a concern regarding patients with pre-existing auto-immune diseases (PAD) undergoing immunotherapy. Methods: An electronic search was performed (Medline) to identify cases of patients with PAD treated with immune checkpoint inhibitors (ICI). Results: Published data are rather limited but continue to emerge. Patients with PAD exhibit a high risk of PAD flare and/or de novo ir-AE. In most cases PAD flares and de novo irAEs were not severe and could be managed effectively with standard treatment. Conclusions: This risk in patients with PAD appears acceptable, and therefore, these patients could receive immunotherapy under close monitoring. Collaboration of oncologists and rheumatologists for the management of these patients is crucial.Kalliopi KlavdianouKonstantinos MelissaropoulosAlexandra FilippopoulouDimitrios DaoussisPCO Convin S.A.articleimmune checkpoint inhibitorscancer immunotherapy pre-existing rheumatic diseasesrheumatic diseasesDiseases of the musculoskeletal systemRC925-935ENMediterranean Journal of Rheumatology, Vol 32, Iss 3, Pp 218-226 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint inhibitors cancer immunotherapy pre-existing rheumatic diseases rheumatic diseases Diseases of the musculoskeletal system RC925-935
spellingShingle	immune checkpoint inhibitors cancer immunotherapy pre-existing rheumatic diseases rheumatic diseases Diseases of the musculoskeletal system RC925-935 Kalliopi Klavdianou Konstantinos Melissaropoulos Alexandra Filippopoulou Dimitrios Daoussis Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
description	Background: Cancer immunotherapy is rapidly expanding but its clinical efficacy is hampered by immune related adverse events (ir-AE). There is a concern regarding patients with pre-existing auto-immune diseases (PAD) undergoing immunotherapy. Methods: An electronic search was performed (Medline) to identify cases of patients with PAD treated with immune checkpoint inhibitors (ICI). Results: Published data are rather limited but continue to emerge. Patients with PAD exhibit a high risk of PAD flare and/or de novo ir-AE. In most cases PAD flares and de novo irAEs were not severe and could be managed effectively with standard treatment. Conclusions: This risk in patients with PAD appears acceptable, and therefore, these patients could receive immunotherapy under close monitoring. Collaboration of oncologists and rheumatologists for the management of these patients is crucial.
format	article
author	Kalliopi Klavdianou Konstantinos Melissaropoulos Alexandra Filippopoulou Dimitrios Daoussis
author_facet	Kalliopi Klavdianou Konstantinos Melissaropoulos Alexandra Filippopoulou Dimitrios Daoussis
author_sort	Kalliopi Klavdianou
title	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
title_short	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
title_full	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
title_fullStr	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
title_full_unstemmed	Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
title_sort	should we be afraid of immune check point inhibitors in cancer patients with pre-existing rheumatic diseases? immunotherapy in pre-existing rheumatic diseases
publisher	PCO Convin S.A.
publishDate	2021
url	https://doaj.org/article/5901a31e50854285a3a7d0f1078a6873
work_keys_str_mv	AT kalliopiklavdianou shouldwebeafraidofimmunecheckpointinhibitorsincancerpatientswithpreexistingrheumaticdiseasesimmunotherapyinpreexistingrheumaticdiseases AT konstantinosmelissaropoulos shouldwebeafraidofimmunecheckpointinhibitorsincancerpatientswithpreexistingrheumaticdiseasesimmunotherapyinpreexistingrheumaticdiseases AT alexandrafilippopoulou shouldwebeafraidofimmunecheckpointinhibitorsincancerpatientswithpreexistingrheumaticdiseasesimmunotherapyinpreexistingrheumaticdiseases AT dimitriosdaoussis shouldwebeafraidofimmunecheckpointinhibitorsincancerpatientswithpreexistingrheumaticdiseasesimmunotherapyinpreexistingrheumaticdiseases
_version_	1718442716775317504

Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases

Ejemplares similares